Zobrazeno 1 - 10
of 62
pro vyhledávání: '"Paolo M. Renzi"'
Autor:
Jean-Paul Collet, Thierry Ducruet, Seema Haider, Stan Shapiro, Ann Robinson, Paolo M Renzi, André-Pierre Contandriopoulos, Pierre Ernst
Publikováno v:
Canadian Respiratory Journal, Vol 8, Iss 1, Pp 27-33 (2001)
RATIONALE: OM-85 BV, an immunostimulant made from bacterial extracts, has been shown to reduce the risk of hospitalization for acute exacerbation in patients with chronic obstructive pulmonary disease, as well as to reduce the length of stay for all
Externí odkaz:
https://doaj.org/article/088ab60219554808a4436557be9e1530
Autor:
Paolo M Renzi
Publikováno v:
Canadian Respiratory Journal, Vol 2, Iss Suppl A, Pp 5A-9A (1995)
The objective of this paper is to describe the important clinical, physiological, immunological and biological similarities among asthmatic infants, children and adults. A comparison of the reported clinical presentation, physiological changes, histo
Externí odkaz:
https://doaj.org/article/f2438d7c42f3461cb180237f57452e95
Autor:
Marc E. Rothenberg, Michael E. Wechsler, Jatin Patel, Calman Prussin, Hector Ortega, Roland Kolbeck, Gail M. Gauvreau, Hans-Uwe Simon, Florence Roufosse, Patricia C. Fulkerson, Bruce S. Bochner, Tim Henkel, Dagmar Simon, Amy D. Klion, Paolo M. Renzi, Sameer K. Mathur, Gerald J. Gleich, Andrew J. Wardlaw, Peter F. Weller
Publikováno v:
The Journal of allergy and clinical immunology
Journal of allergy and clinical immunology, 130 (3
Journal of allergy and clinical immunology, 130 (3
Hypereosinophilic syndromes (HESs) are a diverse group of conditions characterized by clinical manifestations attributable to eosinophilia and eosinophilic infiltration of tissues. HESs are chronic disorders with significant morbidity and mortality.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::08f7e47dfb732adf8e404035da8f4eed
Publikováno v:
Future Medicinal Chemistry. 3:1647-1662
Reversing inflammatory lung disease remains the foremost challenge in treating respiratory diseases such as asthma and chronic obstructive pulmonary disease. Reducing (or modifying) the underlying inflammatory process with mono-target drugs has prove
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d2f4d91d2399c6ce5d7f50fc021d2b81
https://doi.org/10.4155/fmc.11.108
https://doi.org/10.4155/fmc.11.108
Autor:
R. Seguin, J. Gauthier, Rene Pageau, Richard M. Watson, Paolo M. Renzi, Mark Parry-Billings, Gail M. Gauvreau, D. Carballo, M. Mistry, Heather Campbell, Kieran J. Killian, Helene D'anjou
Publikováno v:
Allergy. 66:1242-1248
To cite this article: Gauvreau GM, Pageau R, Seguin R, Carballo D, Gauthier J, D’Anjou H, Campbell H, Watson R, Mistry M, Parry-Billings M, Killian K, Renzi PM. Dose–response effects of TPI ASM8 in asthmatics after allergen. Allergy 2011; 66: 124
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4982a4da767ef5a5f17b3cf6a485d544
https://doi.org/10.1111/j.1398-9995.2011.02638.x
https://doi.org/10.1111/j.1398-9995.2011.02638.x
Autor:
Paolo M. Renzi, James G. Wagner, Nicolay Ferrari, Julie Brault, Marylène Fortin, Jack R. Harkema, Luc Paquet
Publikováno v:
Cytokine. 52:194-202
Background Allergic rhinitis (AR) and asthma are closely related conditions that often co-exist, and are characterized by a Th2 inflammatory response where eosinophils occupy a predominant role. Strategies aimed at blocking signaling through the CC c
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5dce643d1281ea4f75b06ed3a27f7f08
https://doi.org/10.1016/j.cyto.2010.07.005
https://doi.org/10.1016/j.cyto.2010.07.005
Publikováno v:
Respiratory Medicine. 104:510-517
SummaryBackgroundThe role of combination ICS/LABA as initial controller therapy in mild, persistent asthma is uncertain. Therefore, the objective of this study was to compare the efficacy of initial controller therapy with fluticasone propionate (FP)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ead7db743a3b3109ffb1f74f641cc86e
https://doi.org/10.1016/j.rmed.2009.10.025
https://doi.org/10.1016/j.rmed.2009.10.025
Autor:
Bruno Paradis, Gail M. Gauvreau, Diane Lougheed, Paul M. O'Byrne, Catherine Lemière, Ron Olivenstein, Paolo M. Renzi, Louis-Philippe Boulet, Rene Pageau
Publikováno v:
Respiratory Medicine. 103:1159-1166
Summary Background TPI 1020 is a novel compound with potential for anti-neutrophil effects. TPI 1020 exerts its effects by a dual mechanism of action involving corticosteroid activity and controlled donation of nitric oxide. Objectives We assessed th
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b55d3f30e6cadccbfb73eefb054ad274
https://doi.org/10.1016/j.rmed.2009.02.011
https://doi.org/10.1016/j.rmed.2009.02.011
Autor:
Karen Howie, Louis-Philippe Boulet, Adrian J Baatjes, Tara X. Strinich, Donald W. Cockcroft, MyLinh Duong, Beth E. Davis, Richard M. Watson, Paul M. O'Byrne, Paolo M. Renzi, Francine Deschesnes, Gail M. Gauvreau, Johanne Côté
Publikováno v:
American Journal of Respiratory and Critical Care Medicine. 177:952-958
The drug product TPI ASM8 contains two modified phosphorothioate antisense oligonucleotides designed to inhibit allergic inflammation by down-regulating human CCR3 and the common beta chain (beta(c)) of IL-3, IL-5, and granulocyte-macrophage colony-s
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a8a8953f38d8067dd6e83190be242783
https://doi.org/10.1164/rccm.200708-1251oc
https://doi.org/10.1164/rccm.200708-1251oc
Autor:
Masad J. Damha, Denis Bergeron, Luc Paquet, Paolo M. Renzi, Maria M. Mangos, Anna-Lisa Tedeschi, Nicolay Ferrari
Publikováno v:
Annals of the New York Academy of Sciences. 1082:91-102
Antisense oligonucleotides (AON) are being developed for a wide array of therapeutic applications. Significant improvements in their serum stability, target affinity, and safety profile have been achieved with the development of chemically modified o
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c0ef69b05e3b321f7cda6c2e3c69685a
https://doi.org/10.1196/annals.1348.032
https://doi.org/10.1196/annals.1348.032